News Updates
Scope
Catalyst

Fri, Jun 12, 2026

1 updates
NVS
5:36 AM

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido ® (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a...

Trial Results • Phase 3EAACI presentation Fri, Jun 12, 2026novartis.com

Thu, Jun 11, 2026

1 updates

Thu, Jun 4, 2026

1 updates
NVS
6:15 AM

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia ® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN) 1 ,2 . Results were published in The Lancet and presented at the European Renal Association (ERA) Congress....

Trial Results • Phase 3presentation Thu, Jun 4, 2026novartis.com

Wed, Jun 3, 2026

1 updates

Sun, Mar 29, 2026

1 updates
NVS
1:15 AM

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta ® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo 1...

Trial Results • Phase 3novartis.com